Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Soft Genetics' NextGene; BGI Tech's Ultra Deep De Novo; CLC Bio's Microbial Genome

Premium

SoftGenetics has released version 2.3.2 of its NextGene sequencing analysis software. The release includes applications for copy number variant analysis, HLA analysis, as well as a somatic mutation mining tool that can be used with all available sequencing platforms.


BGI Tech has launched Ultra-Deep De Novo, an assembly algorithm that adopts the firm's SOAPdenovo2 assembly software and heterozygous sequence processing algorithm. The tool classifies heterozygous regions within the genome, following ultra-deep sequencing greater than 200-fold coverage.


CLC Bio has launched CLC Microbial Genome Finishing Module, an add-on module to CLC Genomics Workbench. The module includes tools to align and analyze contigs, collect paired reads statistics, create amplicons and primers, add reads to contigs, sample reads and find sequence, reassemble regions, and extend contigs.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.